Getty Realty Corp (GTY) investors sentiment decreased to 1.52 in 2017 Q4. It’s down -2.03, from 3.55 in 2017Q3. The ratio has worsened, as 82 funds started new and increased positions, while 54 reduced and sold equity positions in Getty Realty Corp. The funds in our database now own: 24.90 million shares, down from 47.94 million shares in 2017Q3. Also, the number of funds holding Getty Realty Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 18 Reduced: 36 Increased: 55 New Position: 27.
In a note revealed to investors on 25 May, Biomarin Pharmaceutical (NASDAQ:BMRN) stock Buy was reaffirmed at Canaccord Genuity. They currently have a $105 target price on the stock. Canaccord Genuity’s target price would suggest a potential upside of 18.94% from the company’s last close price.
Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on August, 1. They expect $-0.05 earnings per share, 0.00% or $0.00 from last year’s $-0.05 per share. After $-0.08 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.60 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.
Investors sentiment increased to 1.21 in Q4 2017. Its up 0.08, from 1.13 in 2017Q3. It improved, as 37 investors sold BioMarin Pharmaceutical Inc. shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported. 38,674 were accumulated by Principal Group Inc. University Of Notre Dame Du Lac holds 1.19% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 64,338 shares. 140 are owned by Jnba Financial. Catawba Cap Va reported 3,300 shares. 30,000 are held by Comgest Glob Sas. Moreover, Bailard has 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 4,100 shares. Toth Financial Advisory accumulated 400 shares. Ls Investment Advisors Limited Liability Co stated it has 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Eventide Asset Management Ltd stated it has 0.35% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Clarivest Asset Ltd Llc stated it has 3 shares or 0% of all its holdings. Stanley, a Alabama-based fund reported 64,933 shares. Illinois-based Northern Corporation has invested 0.03% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Plante Moran Finance invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 10,015 were accumulated by Kopp Invest Advsrs Ltd Limited Liability Company. Symphony Asset Ltd Com holds 0.06% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 6,450 shares.
Since December 14, 2017, it had 0 insider buys, and 26 selling transactions for $25.15 million activity. 30,000 shares valued at $2.72M were sold by Davis George Eric on Thursday, February 1. On Thursday, March 15 BIENAIME JEAN JACQUES sold $1.27M worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 15,000 shares. Shares for $169,774 were sold by Ajer Jeffrey Robert on Monday, April 2. On Tuesday, January 2 the insider LAWLIS V BRYAN sold $333,150. FUCHS HENRY J sold $1.34 million worth of stock. On Monday, April 30 Mueller Brian sold $219,275 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 2,450 shares. The insider SPIEGELMAN DANIEL K sold $908,497.
The stock decreased 0.20% or $0.18 during the last trading session, reaching $88.28. About 950,764 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since May 25, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.
More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Streetinsider.com which released: “BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $98 at RBC Capital” on May 25, 2018, also Bizjournals.com with their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018, Seekingalpha.com published: “BioMarin’s valoctocogene roxaparvovec shows long-term treatment effect in hemophilia A study” on May 22, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Benzinga.com and their article: “The Week Ahead: Target, Best Buy Help Close Out Earnings Season” published on May 23, 2018 as well as Streetinsider.com‘s news article titled: “BioMarin Pharma (BMRN) Should Not Be Selling Off on Heme Data – Citi” with publication date: May 22, 2018.
Among 28 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. BioMarin Pharmaceutical has $175 highest and $89 lowest target. $117.50’s average target is 33.10% above currents $88.28 stock price. BioMarin Pharmaceutical had 94 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Wednesday, December 20 by Wedbush. The firm earned “Buy” rating on Friday, February 23 by Stifel Nicolaus. J.P. Morgan maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, April 26 with “Buy” rating. Jefferies maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Thursday, August 24. Jefferies has “Buy” rating and $116.0 target. As per Tuesday, February 27, the company rating was maintained by RBC Capital Markets. The firm earned “Buy” rating on Thursday, December 8 by Gabelli. The rating was upgraded by Goldman Sachs to “Conviction Buy” on Monday, March 7. The stock has “Buy” rating by J.P. Morgan on Tuesday, July 11. On Wednesday, November 15 the stock rating was maintained by Wedbush with “Hold”. The company was maintained on Monday, June 26 by Stifel Nicolaus.
Ingalls & Snyder Llc holds 0.63% of its portfolio in Getty Realty Corp. for 506,667 shares. Chatham Capital Group Inc. owns 33,235 shares or 0.25% of their US portfolio. Moreover, Campbell & Co Investment Adviser Llc has 0.2% invested in the company for 9,847 shares. The California-based Menta Capital Llc has invested 0.18% in the stock. Bowling Portfolio Management Llc, a Ohio-based fund reported 37,152 shares.
More recent Getty Realty Corp. (NYSE:GTY) news were published by: Seekingalpha.com which released: “Who’s Ready To Fill Up With Getty?” on May 24, 2018. Also Globenewswire.com published the news titled: “New Research Coverage Highlights Wintrust Financial, InfraREIT, Innophos, Western Gas Equity Partners, LP, Getty …” on May 21, 2018. Seekingalpha.com‘s news article titled: “Getty Realty’s (GTY) CEO Christopher Constant on Q1 2018 Results – Earnings Call Transcript” with publication date: May 09, 2018 was also an interesting one.
Getty Realty Corp. is a real estate investment trust. The company has market cap of $1.02 billion. The firm invests in real estate markets of the United States. It has a 20.21 P/E ratio. It specializes in the ownership, leasing and financing of convenience store and gasoline station properties.
Analysts await Getty Realty Corp. (NYSE:GTY) to report earnings on July, 25. They expect $0.44 earnings per share, down 16.98% or $0.09 from last year’s $0.53 per share. GTY’s profit will be $17.50 million for 14.50 P/E if the $0.44 EPS becomes a reality. After $0.42 actual earnings per share reported by Getty Realty Corp. for the previous quarter, Wall Street now forecasts 4.76% EPS growth.